There has been remarkableprogress in the treatment of HF over recent years with the establishment ofguideline-directed medical therapies including: (1) Beta-blockers, (2) renalangiotensin aldosterone system (RAAS) inhibition (i.e., angiotensin-convertingenzyme inhibitor [ACEi], aldosterone receptor blocker [ARB] or angiotensinreceptor-neprilysin inhibitor [ARNI]); (3) mineralocorticoid receptor antagonists(MRA), and (4) sodium-glucose cotransporter-2 inhibitors (SGLT2i). The gene discussed is NR3C2; the disease is hydrops fetalis.